Adenoviral vaccine delivers HPV E7 (with ETSD) to APCs, enhancing MHC I/II presentation and priming Th1-biased HPV-specific T cells; resulting CD8+ CTLs recognize E7 peptides on tumor cells and kill them via perforin/granzyme-mediated cytotoxicity (with CD4+ T-cell help).